ARTICLE | Company News
Gliatech other research news
March 27, 1995 8:00 AM UTC
The Cleveland company received a $100,000 Phase I SBIR from the National Institute of Neurological Disorders and Stroke to use Gliatech's lead H3 receptor antagonist in preclinical models of ADD. ...